Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC

Abstract Introduction Randomized prospective studies on patients with metastatic non‐small‐cell lung cancers (NSCLCs) showed that anti‐programmed death‐1 (PD‐1) agents notably improved 2‐year overall survival (OS) rates, compared to docetaxel. NSCLC patients now receive nivolumab and irradiation, co...

詳細記述

書誌詳細

主要な著者:	Paul Lesueur, Alexandre Escande, Juliette Thariat, Enora Vauléon, Isabelle Monnet, Alexis Cortot, Delphine Lerouge, Serge Danhier, Pascal Dô, Catherine Dubos‐Arvis, Christos Chouaïd, Radj Gervais
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2018-11-01
シリーズ:	Cancer Medicine
主題:	anti‐PD‐1 checkpoint inhibitor: radiotherapy combination nivolumab safety
オンライン･アクセス:	https://doi.org/10.1002/cam4.1825
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!